Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • S156: FRONTLINE ASCIMINIB COMB...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
S156: FRONTLINE ASCIMINIB COMBINATION IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS. THE FASCINATION TRIAL.

S156: FRONTLINE ASCIMINIB COMBINATION IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS. THE FASCINATION TRIAL.

Bibliographic Details
Main Authors: Thomas Ernst, Philipp Le Coutre, Martina Crysandt, Tim H Brümmendorf, Georg-Nikolaus Franke, Thomas Illmer, Andreas Burchert, Fabian Lang, Susanne Saussele, Lino Lars Teichmann, Markus Radsak, Stefan Krause, Jenny Rinke, Christian Fabisch, Thomas Lang, Markus Pfirrmann, Andreas Hochhaus
Format: Article
Language:English
Published: Wiley 2023-08-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/01.HS9.0000967536.34543.a6
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

http://journals.lww.com/10.1097/01.HS9.0000967536.34543.a6

Similar Items

  • PB1972: ASC4START: A PHASE IIIB, OPEN-LABEL, RANDOMIZED STUDY OF ASCIMINIB VERSUS NILOTINIB IN PATIENTS WITH NEWLY DIAGNOSED PH+ CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE
    by: Andreas Hochhaus, et al.
    Published: (2023-08-01)
  • S157: NILOTINIB VS. NILOTINIB + PEG-INTERFERON ΑLPHA INDUCTION AND NILOTINIB OR PEG-INTERFERON ΑLPHA MAINTENANCE THERAPY FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS. THE TIGER TRIAL.
    by: Andreas Hochhaus, et al.
    Published: (2023-08-01)
  • P674: 2ND-LINE PONATINIB IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML-CP) PATIENTS FAILING OR INTOLERANT TO 1ST-LINE 2ND GENERATION TKI THERAPY: INTERIM ANALYSIS OF THE PROSPECTIVE PONS TRIAL
    by: Philipp Le Coutre, et al.
    Published: (2023-08-01)
  • Asciminib in chronic myeloid leukemia: a STAMP for expedited delivery?
    by: Sandeep Padala, et al.
    Published: (2023-04-01)
  • S155: EFFICACY AND SAFETY RESULTS FROM ASCEMBL, A PHASE 3 STUDY OF ASCIMINIB VS BOSUTINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE AFTER ≥2 PRIOR TYROSINE KINASE INHIBITORS: WK 96 UPDATE
    by: D. Rea, et al.
    Published: (2022-06-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs